FDA seeks osteoporosis trial design comments
Executive Summary
FDA is seeking comments to modify 11994 draft guidance on osteoporosis clinical trial design. FDA's 2notice asks "do fracture endpoint trials need to be three years in duration, or could shorter studies provide adequate evidence of a new osteoporosis drug's effectiveness and safety?" and "is it appropriate to use placebo controls in fracture endpoint trials?" An advisory committee generally agreed that such studies could be conducted ethically among low-risk patients (3"The Pink Sheet" Sept. 30, 2002, p. 17)...
You may also be interested in...
Osteoporosis Primary Endpoint Should Remain Fracture Reduction
FDA's revised osteoporosis drug guidance should use fracture reduction as a primary endpoint, while increases in bone mineral density should remain a surrogate endpoint, FDA's Endocrinologic & Metabolic Drugs Advisory Committee said Sept. 25
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.